Index
987
MAO inhibitors (monoamine oxidase
inhibitors).
See
Monoamine
oxidase (MAO) inhibitors
Maraviroc, 127, 137, 141
Marigold leaves and flowers, 966
Marijuana, 3
Mast cell, 228, 230
stabiliser, 864, 865, 877, 880–881
adverse effects, 880
care considerations, 880–881
contraindications and cautions, 880
pharmacokinetics, 880
therapeutic actions and indications,
880
MDMA, 67
Measles, mumps, rubella (MMR)
vaccine, 273, 281, 284
autism and, 278
Measuring systems, 55
Mebendazole, 179, 183, 185–186
Mebeverine, 927
Medical Letter
, 12
Medication errors
preventing, 46–50
nurse and midwife’s role, 49
person’s role, 49
reporting, 49–50
Medicines Adverse Reaction Committee
(MARC), 65
Medicines and Medical Devices Safety
Authority, 65
Medicines Monitoring (M2), 65
Medroxyprogesterone, 607, 608
Mefenamic acid, 247
Mefloquine, 166, 167
Megaloblastic anaemias, 774, 776
agents used to treat, 787–789
adverse effects, 788
care considerations, 788–789
contraindications and cautions, 788
pharmacokinetics, 788
therapeutic actions and indications,
787–788
Megestrol, 212, 214
Melatonin, 966
Meloxicam, 241, 247
Melphalan, 195, 197
Memantine, 492, 494
Menarche, 596, 599
Meningococcal vaccine, 279
Menopausal gonadotrophin, 617, 618
Menopause, 596, 601
combination drugs, 609
hormone replacement therapy (HRT),
612–613
Menstrual cycle, 596, 599–600
Menstruation, 596, 600
Mepivacaine, 425, 426
Mercaptopurine, 200, 201, 203
Meropenem, 87, 97, 98
Mesalazine, 242, 923
Mesna, 197, 198
Mesterolone, 629
Metabolic syndrome, 729, 730
Metabolism, 23, 551, 553, 731–735
cholesterol, 732–733
hyperlipidaemias, 733
treating, 734–735
lipoproteins, 72, 73–74, 732
high-density (HDLs), 729, 732
levels, variation in, 731
low-density (LDLs), 729, 732
Metaraminol, 456, 458, 676
Metastasis, 190, 191
Metformin, 573, 586, 588–589, 590
Methadone, 401, 402
Methamphetamine, 67
Methotrexate, 190, 200, 202, 203
Methoxy polyethylene glycol-epoetin
beta, 777, 778
Methoxyflurane, 420, 422
Methyldopa, 676
Methylnaltrexone, 921
Methylphenidate, 67, 334, 333, 347, 348
school nursing, 349
Methylprednisolone, 539, 542, 543
Metoclopramide, 200, 929, 931, 934
Metoprolol, 471, 482, 676, 714, 716,
722–723
Metronidazole, 163, 172–174, 953
Mianserin, 331
Miconazole, 157, 952
Microfibrillar collagen, 769, 770
Midazolam, 354, 416, 420, 421
Midbrain, 292, 298–299
Midodrine, 677
Midwifery, 42, 43, 49
Mifepristone, 620
Migraine headache, 397, 409–410
drugs for.
See
Antimigraine agents
gender considerations, 410
Milk thistle, 966
Milk vetch, 966
Milrinone, 686, 692
MIMS
, 11
Mineralocorticoids, 536, 542–543,
547–548
adverse effects, 547
care considerations, 548
contraindications and cautions, 547
drug–drug interactions, 547
duration of effect, 539
pharmacokinetics, 547
therapeutic actions and indications,
547
Minocycline, 114
Minoxidil, 666, 674
Miosis, 487, 490
Mirtazapine, 331
Misoprostol, 620, 896, 899, 901,
910–911
Mistletoe leaves, 966
Mitochondria, 72, 75
Mitomycin, 205, 206
Mitotic inhibitors, 191, 209–212
adverse effects, 210
care considerations, 211–212
contraindications and cautions, 210
drug–drug interactions, 210–211
pharmacokinetics, 210
therapeutic actions and indications, 210
Mitoxantrone, 205, 207
MMR vaccine, 281, 284
autism and, 278
Moclobemide, 331
Modafinil, 347
Mometasone furoate, 954
Momordica charantia
, 966
Monoamine oxidase (MAO), 444, 449
Monoamine oxidase (MAO) inhibitors,
316, 323–325
adverse effects, 323–324
care considerations, 325
contraindications and cautions, 323
drug–drug interactions, 324
drug–food interactions, 324
pharmacokinetics, 323
therapeutic actions and indications, 323
Monobactum antibiotic, 104–106, 122
adverse effects, 105
care considerations, 105–106
contraindications and cautions, 105
pharmacokinetics, 105
therapeutic actions and indications, 104
Monoclonal antibodies, 258, 263,
264–265, 266–267
adverse effects, 267
care considerations, 267–268
contraindications and cautions, 267
drug–drug interactions, 267
pharmacokinetics, 267
therapeutic actions and indications,
266–267
Monocytes/macrophages, 228, 230–231
Montelukast, 865, 877–879
“Morning-after” pill, 608, 610, 611
Morphine, 67, 398, 401, 402, 403–404,
406
Motility, 891–892
Motor functions, 300
Moxifloxacin, 106, 107
Mucolytics, 842, 859–861
adverse effects, 860
care considerations, 860–861
contraindications and cautions, 860
pharmacokinetics, 860
therapeutic actions and indications, 859
Mucosal layer, 890
Mucous membranes, 229
Mumps virus vaccine, 281, 284
Mupirocin, 951
Muscarinic receptors, 444, 451
Muscle relaxants, 385–395
adults, 386
centrally acting skeletal muscle
relaxants, 388–390
adverse effects, 389
care considerations, 390
contraindications and cautions, 389
drug–drug interactions, 389
pharmacokinetics, 389
therapeutic actions and indications,
388–389
cerebral palsy, 393–394
children, 386
direct-acting skeletal muscle relaxants,
390–393
adverse effects, 391–392
